2-Fluoro-4-demethoxydaunomycin is a synthetic derivative of daunomycin, an anthracycline antibiotic known for its antitumor properties. This compound features a fluorine atom at the second position and lacks a methoxy group at the fourth position of the daunosamine sugar moiety, which alters its biological activity and pharmacological profile. The presence of the fluorine atom can enhance the compound's stability and influence its interaction with biological targets, potentially improving its efficacy against certain cancer types. Like other anthracyclines, 2-fluoro-4-demethoxydaunomycin intercalates into DNA, disrupting replication and transcription processes, which ultimately leads to cell death. Its structure contributes to its ability to generate reactive oxygen species, further enhancing its cytotoxic effects. The compound is of interest in cancer research, particularly in the development of novel chemotherapeutic agents with improved selectivity and reduced side effects compared to traditional treatments. As with many anthracyclines, careful consideration of its pharmacokinetics and potential cardiotoxicity is essential in therapeutic applications.

2-fluoro-4-demethoxydaunomycin

118243-76-8: 2-Fluoro-4-demethoxydaunomycin is a synthetic derivative of daunomycin, an anthracycline antibiotic known for its antitumor properties. This compound features a fluorine atom at the second position and lacks a methoxy group at the fourth position of the daunosamine sugar moiety, which alters its biological activity and pharmacological profile. The presence of the fluorine atom can enhance the compound's stability and influence its interaction with biological targets, potentially improving its efficacy against certain cancer types. Like other anthracyclines, 2-fluoro-4-demethoxydaunomycin intercalates into DNA, disrupting replication and transcription processes, which ultimately leads to cell death. Its structure contributes to its ability to generate reactive oxygen species, further enhancing its cytotoxic effects. The compound is of interest in cancer research, particularly in the development of novel chemotherapeutic agents with improved selectivity and reduced side effects compared to traditional treatments. As with many anthracyclines, careful consideration of its pharmacokinetics and potential cardiotoxicity is essential in therapeutic applications.

CAS 118243-76-8

2-fluoro-4-demethoxydaunomycin